Alphatec Holdings, Inc. (NASDAQ:ATEC) Director Buys $50,700.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATECGet Rating) Director James L. L. Tullis bought 7,500 shares of the stock in a transaction on Wednesday, June 15th. The stock was purchased at an average cost of $6.76 per share, for a total transaction of $50,700.00. Following the acquisition, the director now directly owns 187,558 shares of the company’s stock, valued at approximately $1,267,892.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ:ATEC opened at $6.79 on Thursday. The stock’s 50-day moving average price is $9.48 and its two-hundred day moving average price is $10.54. The company has a current ratio of 2.62, a quick ratio of 1.76 and a debt-to-equity ratio of 7.78. Alphatec Holdings, Inc. has a 12-month low of $6.61 and a 12-month high of $16.47. The firm has a market cap of $690.94 million, a price-to-earnings ratio of -4.12 and a beta of 1.59.

Alphatec (NASDAQ:ATECGet Rating) last released its quarterly earnings data on Thursday, May 5th. The medical technology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.14). Alphatec had a negative return on equity of 147.10% and a negative net margin of 60.83%. The firm had revenue of $70.93 million during the quarter, compared to analysts’ expectations of $67.72 million. As a group, research analysts forecast that Alphatec Holdings, Inc. will post -1.31 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ATEC. Wells Fargo & Company MN increased its position in Alphatec by 30.7% during the 2nd quarter. Wells Fargo & Company MN now owns 131,286 shares of the medical technology company’s stock worth $2,011,000 after purchasing an additional 30,804 shares in the last quarter. Morgan Stanley increased its position in Alphatec by 69.8% during the 2nd quarter. Morgan Stanley now owns 542,189 shares of the medical technology company’s stock worth $8,306,000 after purchasing an additional 222,958 shares in the last quarter. Citigroup Inc. increased its position in Alphatec by 73.4% during the 3rd quarter. Citigroup Inc. now owns 9,308 shares of the medical technology company’s stock worth $113,000 after purchasing an additional 3,941 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Alphatec by 83.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 314,456 shares of the medical technology company’s stock worth $3,833,000 after purchasing an additional 142,612 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Alphatec by 6.2% in the third quarter. Geode Capital Management LLC now owns 1,182,759 shares of the medical technology company’s stock valued at $14,417,000 after acquiring an additional 69,561 shares in the last quarter. 53.52% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently commented on the company. HC Wainwright increased their price objective on Alphatec from $19.00 to $20.00 in a research note on Friday, May 6th. Piper Sandler decreased their price objective on Alphatec from $22.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 2nd. StockNews.com assumed coverage on Alphatec in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Needham & Company LLC decreased their price objective on Alphatec from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, May 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Alphatec has a consensus rating of “Buy” and an average target price of $18.71.

Alphatec Company Profile (Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Recommended Stories

Insider Buying and Selling by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.